Insight

Post-Election Shifts in Congressional Oversight, Regulation & Enforcement: What Businesses Should Know

November 17, 2026
8 minute read

Key Takeaways

  • Congressional investigations are likely to expand. Incoming committee leaders could revisit existing information requests, expand inquiries, and use subpoena authority to examine corporate conduct and government relationships.
  • A divided government creates competing expectations. Companies operating under federal approvals, agreements, or enforcement policies may face congressional scrutiny of the same activities.
  • Affordability and pricing practices will remain prominent. Congressional interest in prescription drug pricing, artificial intelligence, personalized pricing, and corporate concentration could generate additional oversight.
  • State enforcement is becoming increasingly important. Changes in state leadership and expanding state antitrust and consumer protection laws may complicate compliance and transaction planning.

The 2026 midterm elections have set the stage for significant changes in congressional oversight, regulatory priorities, and enforcement activity heading into 2027. With Democrats preparing to control both chambers of Congress and the Trump administration continuing to direct federal agencies, businesses face a period of divided government in which competing policy priorities may create new legal, operational, and reputational risks.

The changing political landscape will affect more than legislative agendas: changes in congressional committee leadership and investigative priorities, together with continued state enforcement activity, could reshape how companies approach government relationships, pricing practices, regulatory compliance, and transactions.

For businesses, the central challenge will be anticipating where congressional and executive branch priorities may diverge, understanding how existing inquiries could develop into formal investigations, and preparing for heightened scrutiny across multiple jurisdictions.

A NEW CONGRESSIONAL LANDSCAPE TAKES SHAPE

Democrats’ gains in the House and Senate will shift control of congressional committees and their investigative agendas beginning in January 2027. The incoming majority is expected to hold as many as 260 House seats and likely 56 Senate seats, although some races remained unresolved immediately following the election.

These changes will have substantial implications for legislative priorities, particularly in areas involving tax and trade, healthcare affordability, technology, financial services, and labor policy.

Congressional committees may prioritize legislative proposals addressing the administration’s tariff authority, prescription drug pricing agreements, healthcare subsidies, and changes to Medicaid. Technology-related priorities may include AI governance, consumer privacy, data center development, and competition in digital markets.

Leadership changes will also affect the Senate confirmation process, potentially limiting the administration’s ability to fill certain agency and commission positions.

However, a divided government may constrain the passage of major legislation. Congressional investigations could therefore become an especially important means of influencing policy, examining executive branch decisions, and scrutinizing private sector conduct. Even when investigations do not result in legislation or findings of unlawful conduct, they can generate significant document demands, public attention, and reputational considerations for companies.

CONGRESSIONAL INVESTIGATIONS LIKELY TO GAIN MOMENTUM

One significant development for businesses may be the transition of existing minority-party inquiries into potential majority-led investigations.

Congressional investigations differ significantly from traditional regulatory enforcement and litigation. Within constitutional and legislative-purpose limitations, Congress can examine conduct that lawmakers consider contrary to public policy even when that conduct is lawful. Investigations can involve document requests, executive testimony, public hearings, and extensive examination of internal communications.

Recent congressional correspondence offers a concrete roadmap for potential oversight priorities.

On November 5, Senator Richard Blumenthal sent letters to organizations previously questioned about contributions to the White House ballroom project. The letters requested outstanding information by January 4 and warned that compulsory measures could follow if recipients did not cooperate.

The inquiry reflects Senator Blumenthal’s concerns about potential conflicts of interest and whether corporate contributions were associated with favorable government treatment. More broadly, it illustrates how corporate relationships with the federal government, including contributions, contracts, and regulatory interactions, can attract congressional scrutiny even in the absence of established legal violations.

Similarly, an October 26 letter from Representative Jamie Raskin questioned industry associations about transactions involving Russian diesel imports that the administration had sought to authorize. The letter raised questions about whether executive branch authorization could conflict with statutory restrictions.

The implications extend beyond energy and sanctions. Companies relying on government licenses, exemptions, contracts, grants, or regulatory approvals may encounter congressional inquiries challenging the legal or policy basis for those decisions.

Pharmaceutical companies face similar considerations. On November 9, senior congressional Democrats requested unredacted agreements from 27 pharmaceutical companies that had negotiated drug pricing arrangements with the administration. Lawmakers raised questions about potential concessions, including tariff relief and regulatory advantages, and whether the agreements would deliver anticipated consumer benefits.

These examples illustrate a common theme: Companies’ interactions with the government could become the subject of congressional investigation when lawmakers question how those arrangements were negotiated or implemented.

While individual lawmakers’ information requests generally lack the compulsory force of committee subpoenas, those requests can establish an investigative record. Once committee leadership changes, previously unanswered or dormant inquiries may provide the foundation for document demands, hearings, and testimony.

AFFORDABILITY AND PRICING PRACTICES DRAW GREATER ATTENTION

Affordability emerged as a central issue during the election and is likely to influence congressional oversight across industries.

Lawmakers have demonstrated particular interest in how companies use AI, algorithms, and consumer data to establish individualized prices, sometimes referred to as surveillance pricing.

This interest crosses party lines: during 2026, House Oversight and Government Reform Committee Chairman James Comer examined the use of AI and consumer data in pricing decisions. Democratic lawmakers, including Representatives Robert Garcia and Frank Pallone, separately requested information from companies concerning their pricing practices.

Those inquiries have reached major corporations, airlines, and rideshare companies, reflecting the potential breadth of congressional scrutiny.

Changes in committee leadership could expand existing inquiries into more extensive investigations of pricing algorithms, internal business decisions, and consumer data practices. Companies may face questions about how pricing tools operate, what information they use, and whether their implementation raises competition or consumer protection concerns.

These issues also intersect with broader congressional interest in prescription drug costs, housing affordability, and competition among major technology companies.

STATE ENFORCEMENT ADDS ANOTHER LAYER OF COMPLEXITY

The federal government is only one part of the changing enforcement landscape.

The election produced significant changes in state governments and attorneys general offices, potentially affecting regulatory priorities and enforcement approaches across the country.

State attorneys general have increasingly pursued antitrust investigations and litigation independently of federal agencies. In some matters, states have challenged transactions approved by the US Department of Justice (DOJ) or continued litigation after federal authorities sought resolution.

Consequently, a favorable outcome with the DOJ or Federal Trade Commission may not resolve every antitrust concern.

Businesses must also navigate an expanding patchwork of state laws governing mergers, pricing algorithms, and consumer data.

Several states have adopted or developed their own premerger notification requirements, sometimes referred to as mini-Hart-Scott-Rodino (HSR) laws. These requirements can create additional filing obligations and opportunities for state review. California’s new premerger notification law is scheduled to take effect January 1, 2027.

State approaches to pricing practices are also diverging:

  • California has amended its Cartwright Act to address certain uses of common pricing algorithms that may facilitate coordination among competitors.
  • New York requires disclosures for certain pricing practices involving algorithms and consumers’ personal information; the requirement is subject to ongoing litigation.
  • Maryland has adopted restrictions addressing personalized pricing in grocery stores.
  • Connecticut has enacted broad restrictions scheduled to affect retail pricing beginning in July 2027.
  • New Jersey has enacted restrictions on personalized pricing for groceries and other specified products, with the principal provisions scheduled to take effect in August 2027; the law also provides for private enforcement under the state’s consumer fraud framework.

For companies operating nationally, these developments create a more complex compliance environment in which practices permitted under one state’s framework may face different requirements elsewhere.

PREPARING FOR CONGRESSIONAL AND REGULATORY SCRUTINY IN 2027

Businesses need not assume that every congressional inquiry will lead to a subpoena or undertake expansive internal reviews in anticipation of hypothetical investigations. Targeted preparation, however, can improve their ability to respond efficiently when scrutiny arises.

Organizations should consider several practical steps:

  • Inventory existing congressional activity. Identify prior letters, information requests, testimony, document productions, and unresolved inquiries, particularly those involving lawmakers who may assume committee leadership.
  • Map potential investigative exposure. Evaluate which committees and subcommittees have jurisdiction over the company’s operations, government relationships, and industry practices.
  • Assess document readiness. Review records retention and preservation procedures, including the ability to implement appropriate legal holds promptly.
  • Review the existing record. Consider how prior disclosures, public statements, internal communications, and government interactions could be interpreted in a congressional investigation.
  • Coordinate internal response teams. Establish processes connecting legal, compliance, government affairs, communications, and business leadership to manage requests and potential testimony.
  • Anticipate parallel proceedings. Evaluate how congressional inquiries could intersect with federal or state enforcement, regulatory investigations, shareholder litigation, or other private claims.

As the 120th Congress prepares to convene, organizations should closely monitor committee leadership decisions, emerging investigative priorities, and state regulatory developments.

The post-election transition offers businesses an opportunity to move from reactive congressional response to proactive oversight risk management. Understanding existing exposure, preserving a defensible record, and establishing coordinated response procedures can help organizations navigate the competing demands of government oversight and regulatory compliance in 2027.